company background image

Arab DrugCASE:ADCI Stock Report

Market Cap







17 Oct, 2021


Company Financials
ADCI fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance3/6
Financial Health6/6

ADCI Overview

The Arab Drug Company produces and sells pharmaceutical products.

Price History & Performance

Summary of all time highs, changes and price drops for Arab Drug
Historical stock prices
Current Share Priceج.م57.07
52 Week Highج.م54.21
52 Week Lowج.م82.22
1 Month Change-5.72%
3 Month Change-11.27%
1 Year Change-9.70%
3 Year Change104.99%
5 Year Change749.26%
Change since IPO358.60%

Recent News & Updates

Shareholder Returns

ADCIEG PharmaceuticalsEG Market

Return vs Industry: ADCI underperformed the EG Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: ADCI underperformed the EG Market which returned 8.2% over the past year.

Price Volatility

Is ADCI's price volatile compared to industry and market?
ADCI volatility
ADCI Beta0.69
Industry Beta0.86
Market Beta1

Stable Share Price: ADCI is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: ADCI's weekly volatility (2%) has been stable over the past year.

About the Company

19631,148R. Samah Abdel-Yassiz

The Arab Drug Company produces and sells pharmaceutical products. It offers ampoules, tablets, syrups, solutions, capsules, aerosol sprays, metered dose inhalers, granulated powder for suspension, creams, ointments, and suppositories. The company was incorporated in 1963 and is based in Cairo, Egypt.

Arab Drug Fundamentals Summary

How do Arab Drug's earnings and revenue compare to its market cap?
ADCI fundamental statistics
Market Capج.م342.42m
Earnings (TTM)ج.م102.04m
Revenue (TTM)ج.م537.05m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADCI income statement (TTM)
Cost of Revenueج.م306.75m
Gross Profitج.م230.30m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date


Earnings per share (EPS)17.01
Gross Margin42.88%
Net Profit Margin19.00%
Debt/Equity Ratio6.8%

How did ADCI perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Arab Drug undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: ADCI (EGP57.07) is trading above our estimate of fair value (EGP46.75)

Significantly Below Fair Value: ADCI is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: ADCI is good value based on its PE Ratio (3.4x) compared to the EG Pharmaceuticals industry average (5.5x).

PE vs Market: ADCI is good value based on its PE Ratio (3.4x) compared to the EG market (12.3x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADCI's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ADCI is good value based on its PB Ratio (1.1x) compared to the EG Pharmaceuticals industry average (1.3x).

Future Growth

How is Arab Drug forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Arab Drug has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Arab Drug performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ADCI has a high level of non-cash earnings.

Growing Profit Margin: ADCI's current net profit margins (19%) are higher than last year (17.8%).

Past Earnings Growth Analysis

Earnings Trend: ADCI's earnings have grown significantly by 33.6% per year over the past 5 years.

Accelerating Growth: ADCI's earnings growth over the past year (10%) is below its 5-year average (33.6% per year).

Earnings vs Industry: ADCI earnings growth over the past year (10%) underperformed the Pharmaceuticals industry 10%.

Return on Equity

High ROE: ADCI's Return on Equity (33%) is considered high.

Financial Health

How is Arab Drug's financial position?

Financial Position Analysis

Short Term Liabilities: ADCI's short term assets (EGP375.1M) exceed its short term liabilities (EGP136.6M).

Long Term Liabilities: ADCI has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: ADCI's debt to equity ratio (6.8%) is considered satisfactory.

Reducing Debt: ADCI's debt to equity ratio has reduced from 19.5% to 6.8% over the past 5 years.

Debt Coverage: ADCI's debt is well covered by operating cash flow (172.5%).

Interest Coverage: ADCI earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet


What is Arab Drug current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ADCI's dividend (4.38%) is higher than the bottom 25% of dividend payers in the EG market (2.69%).

High Dividend: ADCI's dividend (4.38%) is low compared to the top 25% of dividend payers in the EG market (7.43%).

Stability and Growth of Payments

Stable Dividend: ADCI has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: ADCI's dividend payments have increased, but the company has only paid a dividend for 9 years.

Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (18.2%), ADCI's dividend payments are well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


R. Samah Abdel-Yassiz

no data


Dr. R. Samah Mustafa Abdel-Yassiz serves as the Chairman of the Board and Managing Director at The Arab Drug Company.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

The Arab Drug Company's employee growth, exchange listings and data sources

Key Information

  • Name: The Arab Drug Company
  • Ticker: ADCI
  • Exchange: CASE
  • Founded: 1963
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م342.420m
  • Shares outstanding: 6.00m
  • Website:

Number of Employees


  • The Arab Drug Company
  • 5 EL Massanei Street
  • AL Amireya
  • Cairo
  • 1343
  • Egypt


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/17 16:16
End of Day Share Price2021/10/17 00:00
Annual Earnings2021/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.